Arcadia Biosciences Net Worth
Arcadia Biosciences Net Worth Breakdown | RKDA |
Arcadia Biosciences Net Worth Analysis
Arcadia Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Arcadia Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Arcadia Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Arcadia Biosciences' net worth analysis. One common approach is to calculate Arcadia Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Arcadia Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Arcadia Biosciences' net worth. This approach calculates the present value of Arcadia Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Arcadia Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Arcadia Biosciences' net worth. This involves comparing Arcadia Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Arcadia Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Arcadia Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Arcadia Biosciences' net worth research are outlined below:
| Arcadia Biosciences generated a negative expected return over the last 90 days | |
| Arcadia Biosciences has high historical volatility and very poor performance | |
| Arcadia Biosciences has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 5.33 M. Net Loss for the year was (13.99 M) with profit before overhead, payroll, taxes, and interest of 1.11 M. | |
| Arcadia Biosciences currently holds about 21.23 M in cash with (15.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.96. | |
| Arcadia Biosciences has a poor financial position based on the latest SEC disclosures | |
| Latest headline from businesswire.com: Arcadia Biosciences Announces Date of Fourth Quarter 2024 Financial Results and Business Highlights Conference Call |
Arcadia Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Arcadia Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arcadia Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Arcadia Biosciences Target Price Consensus
Arcadia target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Arcadia Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 2 | Strong Buy |
Most Arcadia analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Arcadia stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Arcadia Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationArcadia Biosciences Target Price Projection
Arcadia Biosciences' current and average target prices are 3.30 and 9.00, respectively. The current price of Arcadia Biosciences is the price at which Arcadia Biosciences is currently trading. On the other hand, Arcadia Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Arcadia Biosciences Market Quote on 21st of March 2025
Target Price
Analyst Consensus On Arcadia Biosciences Target Price
Know Arcadia Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arcadia Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arcadia Biosciences backward and forwards among themselves. Arcadia Biosciences' institutional investor refers to the entity that pools money to purchase Arcadia Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Genworth Financial Wealth Mgmt Inc | 2024-12-31 | 5.0 | Oliver Lagore Vanvalin Investment Group | 2024-09-30 | 4.0 | Harbour Investments, Inc. | 2024-12-31 | 1.0 | Tower Research Capital Llc | 2024-12-31 | 0.0 | Northern Trust Investments N A | 2024-12-31 | 0.0 | U.s. Bancorp | 2024-12-31 | 0.0 | Mariner Wealth Advisors Llc | 2024-12-31 | 25 K | Vanguard Group Inc | 2024-12-31 | 14 K | Ubs Group Ag | 2024-12-31 | 13.9 K | Geode Capital Management, Llc | 2024-12-31 | 12.3 K | State Street Corp | 2024-12-31 | 12.1 K |
Follow Arcadia Biosciences' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 4.69 M.Market Cap |
|
Project Arcadia Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.64) | (0.67) | |
| Return On Capital Employed | (0.99) | (1.04) | |
| Return On Assets | (0.64) | (0.67) | |
| Return On Equity | (1.25) | (1.19) |
When accessing Arcadia Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Arcadia Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Arcadia Biosciences' profitability and make more informed investment decisions.
Please note, the presentation of Arcadia Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arcadia Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Arcadia Biosciences' management manipulating its earnings.
Evaluate Arcadia Biosciences' management efficiency
Arcadia Biosciences has return on total asset (ROA) of (0.4471) % which means that it has lost $0.4471 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6708) %, meaning that it created substantial loss on money invested by shareholders. Arcadia Biosciences' management efficiency ratios could be used to measure how well Arcadia Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of March 21, 2025, Return On Tangible Assets is expected to decline to -0.67. In addition to that, Return On Capital Employed is expected to decline to -1.04. At present, Arcadia Biosciences' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 5.5 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.5 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.24 | 8.78 | |
| Tangible Book Value Per Share | 9.21 | 8.75 | |
| Enterprise Value Over EBITDA | 0.12 | 0.11 | |
| Price Book Value Ratio | 0.27 | 0.28 | |
| Enterprise Value Multiple | 0.12 | 0.11 | |
| Price Fair Value | 0.27 | 0.28 | |
| Enterprise Value | -1.9 M | -1.8 M |
Management at Arcadia Biosciences focuses on leveraging technology and optimizing operations. We evaluate the impact of these focuses on the company's financial health and stock performance.
Enterprise Value Revenue 0.0438 | Revenue | Quarterly Revenue Growth 0.184 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcadia Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcadia Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcadia Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arcadia Biosciences Corporate Filings
8K | 20th of March 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 14th of February 2025 Other Reports | ViewVerify | |
F4 | 5th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 3rd of January 2025 Other Reports | ViewVerify |
Arcadia Biosciences Earnings Estimation Breakdown
The calculation of Arcadia Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Arcadia Biosciences is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Arcadia Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Arcadia Biosciences Earnings Projection Consensus
Suppose the current estimates of Arcadia Biosciences' value are higher than the current market price of the Arcadia Biosciences stock. In this case, investors may conclude that Arcadia Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Arcadia Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 1 | 46.89% | -0.87 | 0.0 | -6.77 |
Arcadia Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Arcadia Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Arcadia Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Arcadia Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Arcadia Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Arcadia Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Arcadia Biosciences should always be considered in relation to other companies to make a more educated investment decision.Arcadia Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Arcadia Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-12 | 2024-09-30 | -0.81 | -0.87 | -0.06 | 7 | ||
2024-08-13 | 2024-06-30 | 1.55 | 0.78 | -0.77 | 49 | ||
2024-05-22 | 2024-03-31 | -2.21 | -1.78 | 0.43 | 19 | ||
2024-03-28 | 2023-12-31 | -2.58 | -2.52 | 0.06 | 2 | ||
2023-11-09 | 2023-09-30 | -3.19 | -1.44 | 1.75 | 54 | ||
2023-08-10 | 2023-06-30 | -4.8 | -2.65 | 2.15 | 44 | ||
2023-05-11 | 2023-03-31 | -6.85 | -10.86 | -4.01 | 58 | ||
2023-03-30 | 2022-12-31 | -6.8 | -6.29 | 0.51 | 7 | ||
2022-11-10 | 2022-09-30 | -8.4 | -4.8 | 3.6 | 42 | ||
2022-08-11 | 2022-06-30 | -12 | -8.0 | 4.0 | 33 | ||
2022-05-12 | 2022-03-31 | -13.6 | -8.0 | 5.6 | 41 | ||
2022-03-30 | 2021-12-31 | -12 | -11.2 | 0.8 | 6 | ||
2021-11-15 | 2021-09-30 | -11.8 | -4.0 | 7.8 | 66 | ||
2021-08-16 | 2021-06-30 | -10.93 | -9.6 | 1.33 | 12 | ||
2021-05-17 | 2021-03-31 | -13.73 | 4.8 | 18.53 | 134 | ||
2021-03-30 | 2020-12-31 | -16.4 | 35.2 | 51.6 | 314 | ||
2020-11-12 | 2020-09-30 | -21.73 | -24.0 | -2.27 | 10 | ||
2020-08-13 | 2020-06-30 | -23.47 | -41.2 | -17.73 | 75 | ||
2020-05-13 | 2020-03-31 | -21.8 | 11.6 | 33.4 | 153 | ||
2020-03-25 | 2019-12-31 | -23 | -20.0 | 3.0 | 13 | ||
2019-11-06 | 2019-09-30 | -30.8 | -81.6 | -50.8 | 164 | ||
2019-08-14 | 2019-06-30 | -36.2 | 33.6 | 69.8 | 192 | ||
2019-05-08 | 2019-03-31 | -32.4 | -105.6 | -73.2 | 225 | ||
2019-03-27 | 2018-12-31 | -30.4 | -5.6 | 24.8 | 81 | ||
2018-11-07 | 2018-09-30 | -45.2 | 37.2 | 82.4 | 182 | ||
2018-08-08 | 2018-06-30 | -51.6 | -80.8 | -29.2 | 56 | ||
2018-05-09 | 2018-03-31 | -1.4 | -4.86 | -3.46 | 247 | ||
2018-03-20 | 2017-12-31 | -2 | -1.39 | 0.61 | 30 | ||
2017-11-09 | 2017-09-30 | -64 | -72.0 | -8.0 | 12 | ||
2017-08-10 | 2017-06-30 | -88 | -72.0 | 16.0 | 18 | ||
2017-05-10 | 2017-03-31 | -56 | -80.0 | -24.0 | 42 | ||
2017-03-08 | 2016-12-31 | -80 | -104.0 | -24.0 | 30 | ||
2016-11-10 | 2016-09-30 | -56 | -72.0 | -16.0 | 28 | ||
2016-08-09 | 2016-06-30 | -56 | -80.0 | -24.0 | 42 | ||
2016-05-10 | 2016-03-31 | -56 | -96.0 | -40.0 | 71 | ||
2016-03-08 | 2015-12-31 | -56 | -64.0 | -8.0 | 14 | ||
2015-11-05 | 2015-09-30 | -56 | -88.0 | -32.0 | 57 | ||
2015-08-10 | 2015-06-30 | -88 | -152.0 | -64.0 | 72 | ||
2015-06-25 | 2015-03-31 | -88 | -2968.0 | -2880.0 | 3272 |
Arcadia Biosciences Corporate Management
| Belinda Yao | VP Operations | Profile | |
| Brian Schaffer | Senior Sales | Profile | |
| Kevin Hodges | VP Operations | Profile | |
| Mark Kawakami | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Arcadia Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.285 | Earnings Share (6.77) | Revenue Per Share | Quarterly Revenue Growth 0.184 | Return On Assets |
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.